The impact of nutritional status on pancreatic cancer therapy

References

• GBD 2017Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–947.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics. CA Cancer J Clin. 2021 Jan;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55(9–10):1158–1160.
   PubMed Web of Science ®Google Scholar
• Michl P, Löhr M, Neoptolemos JP, et al. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: prevent, detect, and treat the disease earlier and better. United European Gastroenterol J. 2021;9(7):860–871.
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Hammel P, Delpero JR, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1–10.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(24):2545–2556.
   PubMed Web of Science ®Google Scholar
• Javed MA, Beyer G, Le N, et al. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19(1):97–104.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898–2913.
   PubMed Web of Science ®Google Scholar
• Bossi P, Delrio P, Mascheroni A, et al. The spectrum of malnutrition/ cachexia/ sarcopenia in oncology according to different cancer types and settings: A narrative review. Nutrients. 2021;13(6):1980.
   PubMed Web of Science ®Google Scholar
• Stornello C, Archibugi L, Stigliano S, et al. Diagnostic delay does not influence survival of pancreatic cancer patients. United European Gastroenterol J. 2020;8(1):81–90.
   PubMed Web of Science ®Google Scholar
• GLIM Core Leadership Committee; GLIM Working Group, Cederholm T, Jensen GL, Mitd C, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
   PubMed Web of Science ®Google Scholar
• Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136(1):177–186.
   PubMed Web of Science ®Google Scholar
• Coveler AL, Mizrahi J, Eastman B, et al. Precision promise consortium. Pancreas cancer-associated pain management. Oncologist. 2021;26(6):e971–e982.
   PubMed Web of Science ®Google Scholar
• Damm M, Weniger M, Kölsch AK, et al. The quality of pain management in pancreatic cancer: a prospective multi-center study. Pancreatology. 2020;20(7):1511–1518.
   PubMed Web of Science ®Google Scholar
• Ahmed O, Lee JH, Thompson CC, et al. AGA clinical practice update on the optimal management of the malignant alimentary tract obstruction: expert review. Clin Gastroenterol Hepatol. 2021;19(9):1780–1788.
   PubMed Web of Science ®Google Scholar
• ASGE Standards of Practice Committee, Jue TL, Storm AC, Naveed M, et al. ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction. Gastrointest Endosc. 2021;93(2):309–322.e4.
   PubMed Web of Science ®Google Scholar
• Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist. 2010;15(8):913–920.
   PubMed Web of Science ®Google Scholar
• Kordes M, Larsson L, Engstrand L, et al. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124(10):1623–1636.
   PubMed Web of Science ®Google Scholar
• Pettersen K, Andersen S, Degen S, et al. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci Rep. 2017;7:2046.
   PubMed Web of Science ®Google Scholar
• Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6(1):18–25.
   PubMedGoogle Scholar
• Ying H, Kimmelman AC, Lyssiotis C, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656–670.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Z. Zhang Y et al.ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-regulated release of extracellular vesicles from cancer cells. Gastroenterology. 2019;156(3):722–734.
   PubMed Web of Science ®Google Scholar
• Inui A. Neuropeptide Y, a key molecule in anorexia and cachexia in wasting disorders? Mol Med Today. 1999;5(2):79–85
   PubMedGoogle Scholar
• Olson B, Zhu X, Norgard MA, et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat Commun. 2021;12(1):2057.
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Caccialanza R, Capurso G, et al. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers (Basel). 2020;12(2):275.
   Web of Science ®Google Scholar
• Iglesia D, Avci B, Kiriukova M, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United European Gastroenterol J. 8(9): 1115–1125. 2020.
   PubMed Web of Science ®Google Scholar
• Read JA, Crockett N, Volker DH, et al. Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutr Cancer. 2005;1:53–56.
   Google Scholar
• Kondrup J, Allison SP, Elia M, et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22(4):415–421.
   PubMed Web of Science ®Google Scholar
• Orell-Kotikangas H, Österlund P, Saarilahti K, et al. NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients. Support Care Cancer. 2015;23:1495–1502.
   PubMed Web of Science ®Google Scholar
• Wischmeyer PE, Carli F, Evans DC, et al. American Society for Enhanced recovery and perioperative quality initiative joint consensus statement on nutrition screening and therapy within a surgical enhanced recovery pathway. Anesth Analg. 2018;126(6):1883–1895.
   PubMed Web of Science ®Google Scholar
• Blauwhoff-Buskermolen S, Ruijgrok C, Ostelo RW, et al. The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite. Support Care Cancer. 2016;24(2):661–666.
   PubMed Web of Science ®Google Scholar
• Di Somma S, Lukaski HC, Codognotto M, et al. Consensus paper on the use of BIVA (Bioeletrical Impendance Vector Analysis) in medicine for the management of body hydration. Emerg Care J. 2011;7(4):6.
   Google Scholar
• Angrisani M, Sandini M, Cereda M, et al. Preoperative adiposity at bioimpedance vector analysis improves the ability of Fistula Risk Score (FRS) in predicting pancreatic fistula after pancreatoduodenectomy. Pancreatology. 2020;20(3):545–550.
   PubMed Web of Science ®Google Scholar
• Sandini M, Paiella S, Cereda M, et al. Perioperative interstitial fluid expansion predicts major morbidity following pancreatic surgery: appraisal by bioimpedance vector analysis. Ann Surg. 270(5): 923–929. 2019.
   PubMed Web of Science ®Google Scholar
• Keller U. Nutritional laboratory markers in malnutrition. J Clin Med. 2019;8(6):775.
   PubMed Web of Science ®Google Scholar
• Arends J, Bodoky G, Bozzetti F, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr. 2006;25(2):245–259.
   PubMed Web of Science ®Google Scholar
• Qi Q, Geng Y, Sun M, et al. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology. 2015;15(2):145–150.
   PubMed Web of Science ®Google Scholar
• Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int J Mol Sci. 2017;18(4):730.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.
   PubMed Web of Science ®Google Scholar
• Pecorelli N, Carrara G, De Cobelli F, et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016;103(4):434–442.
   PubMed Web of Science ®Google Scholar
• Carrara G, Pecorelli N, De Cobelli F, et al. Preoperative sarcopenia determinants in pancreatic cancer patients. Clin Nutr. 2017;36(6):1649–1653.
   PubMed Web of Science ®Google Scholar
• Pierobon ES, Moletta L, Zampieri S, et al. The prognostic value of low muscle mass in pancreatic cancer patients: a systematic review and meta-analysis. J Clin Med. 10(14): 3033. 2021.
   PubMed Web of Science ®Google Scholar
• Choi Y, Oh DY, Kim TY, et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One. 2015;10(10):e0139749.
   PubMed Web of Science ®Google Scholar
• Pecorelli N, Capretti G, Sandini M, et al. Impact of sarcopenic obesity on failure to rescue from major complications following pancreaticoduodenectomy for cancer: results from a multicenter study. Ann Surg Oncol. 2018;25(1):308–317.
   PubMed Web of Science ®Google Scholar
• Youn S, Chen A, Ha V, et al. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clin Nutr. 2021;40(8):4888–4892.
   PubMed Web of Science ®Google Scholar
• Sandini M, Patino M, Ferrone CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 153(9): 809–815. 2018.
   PubMed Web of Science ®Google Scholar
• Salinas-Miranda E, Deniffel D, Dong X, et al. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol. 2021;31(11):8662–8670.
   PubMed Web of Science ®Google Scholar
• Hsu TH, Schawkat K, Berkowitz SJ, et al. Artificial intelligence to assess body composition on routine abdominal CT scans and predict mortality in pancreatic cancer- A recipe for your local application. Eur J Radiol. 2021;142:109834.
   PubMed Web of Science ®Google Scholar
• Carli F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. Can J Anaesth. 2015 Feb;62(2):110–119.
   PubMed Web of Science ®Google Scholar
• Probst P, Haller S, Bruckner T, et al. Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas). Br J Surg. 2017 Jul;104(8):1053–1062.
   PubMed Web of Science ®Google Scholar
• Gianotti L, Besselink MG, Sandini M, et al. Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018 Nov;164(5):1035–1048.
   PubMed Web of Science ®Google Scholar
• Kirihara Y, Takahashi N, Hashimoto Y, et al. Prediction of pancreatic anastomotic failure after pancreatoduodenectomy: the use of preoperative, quantitative computed tomography to measure remnant pancreatic volume and body composition. Ann Surg. 2013;257(3):512–519.
   PubMed Web of Science ®Google Scholar
• Sandini M, Bernasconi DP, Fior D, et al. A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer. Nutrition. 2016;32(11–12):1231–1237.
   PubMed Web of Science ®Google Scholar
• Roccamatisi L, Gianotti L, Paiella S, et al. Preoperative standardized phase angle at bioimpedance vector analysis predicts the outbreak of antimicrobial-resistant infections after major abdominal oncologic surgery: a prospective trial. Nutrition. 2021 Jun;86:111184.
   PubMed Web of Science ®Google Scholar
• Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: clinical nutrition in surgery. Clin Nutr. 2021 Jul;40(7):4745–4761.
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer pa- tients: a randomized, clinical trial. J Parenter Enteral Nutr. 2000;24(1):7–14 24.
   PubMed Web of Science ®Google Scholar
• Gillis C, Buhler K, Bresee L, et al. Effects of nutritional prehabilitation, with and without exercise, on outcomes of patients who undergo colorectal surgery: a systematic review and meta-analysis. Gastroenterology. 2018 Aug;155(2):391–410.e4.
   PubMed Web of Science ®Google Scholar
• Ausania F, Senra P, Meléndez R, et al. Prehabilitation in patients undergoing pancreaticoduodenectomy: a randomized controlled trial. Rev Esp Enferm Dig. 2019: 111
   PubMed Web of Science ®Google Scholar
• Adiamah A, Skořepa P, Weimann A, et al. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer. Ann Surg. 2019;270(2):247–256.
   PubMed Web of Science ®Google Scholar
• Gade J, Levring T, Hillingsø J, et al. The effect of preoperative oral immunonutrition on complications and length of hospital stay after elective surgery for pancreatic cancer-A randomized controlled trial. Nutr Cancer. 2016;68(2):225–233.
   PubMed Web of Science ®Google Scholar
• Aida T, Furukawa K, Suzuki D, et al. Preoperative immunonutrition decreases postoperative complications by modulating prostaglandin E2 production and T-cell differentiation in patients undergoing pancreatoduodenectomy. Surg (United States). 2014;155:124–133.
   PubMed Web of Science ®Google Scholar
• Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008 Aug;248(2):189–198.
   PubMed Web of Science ®Google Scholar
• Pecorelli N, Nobile S, Partelli S, et al. Enhanced recovery pathways in pancreatic surgery: state of the art. World J Gastroenterol. 2016 Jul 28;22(28):6456–6468.
   PubMed Web of Science ®Google Scholar
• Gianotti L, Biffi R, Sandini M, et al. Preoperative oral carbohydrate load versus placebo in major elective abdominal surgery (PROCY): a randomized, placebo-controlled, multicenter, phase iii trial. Ann Surg. 2018 Apr;267(4):623–630.
   PubMed Web of Science ®Google Scholar
• Braga M, Pecorelli N, Ariotti R, et al. Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg. 2014 Nov;38(11):2960–2966.
   PubMed Web of Science ®Google Scholar
• Trestini I, Carbognin L, Sperduti I, et al. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. Eur J Clin Nutr. 72(5): 772–779. 2018.
   PubMed Web of Science ®Google Scholar
• Maeda A, Boku N, Fukutomi A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 2008 Mar;38(3):227–229.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267–277.
   PubMed Web of Science ®Google Scholar
• European Study Group for Pancreatic Cancer, Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017Mar11;389(10073):1011–1024
   PubMed Web of Science ®Google Scholar
• Akahori T, Sho M, Tanaka T, et al. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Am J Surg. 2016 Apr;211(4):787–792.
   PubMed Web of Science ®Google Scholar
• Yamada D, Eguchi H, Asaoka T, et al. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surg Today. 2017 Nov;47(11):1361–1371.
   PubMed Web of Science ®Google Scholar
• Park JS, Kim HM, Jeung HC, et al. Association between early nutritional risk and overall survival in patients with advanced pancreatic cancer: a single-center retrospective study. Clin Nutr ESPEN. 2019;30:94–99.
   PubMed Web of Science ®Google Scholar
• Takeda T, Sasaki T, Suzumori C, et al. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol. 2021 Jul;26(7):1293–1303.
   PubMed Web of Science ®Google Scholar
• Kurahara H, Maemura K, Mataki Y, et al. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Pancreatology. 2015;15(6):688–693.
   PubMed Web of Science ®Google Scholar
• Jin WH, Mellon EA, Frakes JM, et al. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. J Gastrointest Oncol. 2018;9(1):24–34.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Reni M, Zanon S, Peretti U, et al. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(10):691–697.
   PubMed Web of Science ®Google Scholar
• Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413–423.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–29.
   PubMed Web of Science ®Google Scholar
• Yalcin S, Dane F, Oksuzoglu B, et al. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer. 2020;20(1):259.
   PubMed Web of Science ®Google Scholar
• Carrato A, Cerezo L, Feliu J, et al. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Clin Transl Oncol. 2021. https://doi.org/10.1007/s12094-021-02674-x. Epub ahead of print.
   Google Scholar
• Phillips ME, Robertson MD, Hart K, et al. Long-term changes in nutritional status and body composition in patients with malignant pancreatic disease - A systematic review. Clin Nutr ESPEN. 2021;44:85–95.
   PubMed Web of Science ®Google Scholar
• Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012;44(2):181–191.
   PubMed Web of Science ®Google Scholar
• Naumann P, Habermehl D, Welzel T, et al. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol. 2013;189(9):745–752.
   PubMed Web of Science ®Google Scholar
• Naumann P, Eberlein J, Farnia B, et al. Continued weight loss and sarcopenia predict poor outcomes in locally advanced pancreatic cancer treated with chemoradiation. Cancers (Basel). 2019;11(5):709.
   Web of Science ®Google Scholar
• Naumann P, Eberlein J, Farnia B, et al. Cachectic body composition and inflammatory markers portend a poor prognosis in patients with locally advanced pancreatic cancer treated with chemoradiation. Cancers (Basel). 2019;11(11):1655.
   Web of Science ®Google Scholar
• Shin DW, Kim MA, Lee JC, et al. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. BMC Res Notes. 2021;14(1):272.
   PubMed Web of Science ®Google Scholar
• Cloyd JM, Nogueras-González GM, Prakash LR, et al. Anthropometric changes in patients with pancreatic cancer undergoing preoperative therapy and pancreatoduodenectomy. J Gastrointest Surg. 2018;22(4):703–712.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Yamada S, Sonohara F, et al. Clinical impact of neoadjuvant therapy on nutritional status in pancreatic cancer. Ann Surg Oncol. 2018;25(11):3365–3371.
   PubMed Web of Science ®Google Scholar
• Cooper AB, Slack R, Fogelman D, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:2416–2423.
   PubMed Web of Science ®Google Scholar
• Griffin OM, Duggan SN, Ryan R, et al. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Pancreatology. 2019;19(6):850–857.
   PubMed Web of Science ®Google Scholar
• Trestini I, Cintoni M, Rinninella E, et al. Neoadjuvant treatment: a window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma.world. J Gastrointest Surg. 2021;13(9):885–903.
   Web of Science ®Google Scholar
• Powell-Brett S, de Liguori Carino N, Roberts K. Understanding pancreatic exocrine insufficiency and replacement therapy in pancreatic cancer. Eur J Surg Oncol. 2021;47(3):539–544.
   PubMed Web of Science ®Google Scholar
• Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92–96.
   PubMed Web of Science ®Google Scholar
• Woo SM, Joo J, Kim SY, et al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology. 2016;16(6):1099–1105.
   PubMed Web of Science ®Google Scholar
• Saito T, Nakai Y, Isayama H, et al. A multicenter open-label randomized controlled trial of pancreatic enzyme replacement therapy in unresectable pancreatic cancer. Pancreas. 2018;47(7):800–806.
   PubMed Web of Science ®Google Scholar
• Roberts KJ, Bannister CA, Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: results of a population based study. Pancreatology. 2019;19(1):114–121.
   PubMed Web of Science ®Google Scholar
• Dominguez-Muñoz JE, Nieto-Garcia L, López-Díaz J, et al. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer. 2018;18(1):534.
   PubMedGoogle Scholar
• Trestini I, Carbognin L, Peretti U, et al. pancreatic enzyme replacement therapy in patients undergoing first-line gemcitabine plus nab-paclitaxel for advanced pancreatic adenocarcinoma. Front Oncol. 2021;11:688889. visited on 2021 Oct 20th.
   PubMed Web of Science ®Google Scholar
• Kiriukova M, de La Iglesia Garcia D, Panic N, et al. pancreatic cancer malnutrition and pancreatic exocrine insufficiency in the course of chemotherapy in unresectable pancreatic cancer. Front Med (Lausanne). 2020;7:495.
   PubMed Web of Science ®Google Scholar
• Boon M, Calvo-Lerma J, Claes I. Claes I et al.Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with cystic fibrosis. J Cyst Fibros. 2020;19(4):562–568.
   PubMed Web of Science ®Google Scholar
• Dutch Pancreatic Cancer Group, Mackay TM, Latenstein AEJ, Sprangers MAG, et al. Relationship between quality of life and survival in patients with pancreatic and periampullary cancer: a multicenter cohort analysis. J Natl Compr Canc Netw. 2020;18(10):1354–1363.
   PubMed Web of Science ®Google Scholar